Effects of Fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: A pet study

NeuroImage

Volumn 12, Issue 4, 2000, Pages 452-465

  Moresco, R M ^a   Colombo, C ^b   Fazio, F ^a   Bonfanti, A ^b   Lucignani, G ^a   Messa, C ^a   Gobbo, C ^a   Galli, L ^a   Del Sole, A ^a   Lucca, A ^b   Smeraldi, E ^b  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUORINE 18; FLUORO ETHYL SPIPERONE F 18; FLUVOXAMINE; OXYGEN 18; SEROTONIN UPTAKE INHIBITOR; SPIPERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYCLOTRON; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MENTAL DISEASE; NEURORADIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RADIOCHEMISTRY; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0033778681     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1006/nimg.2000.0619     Document Type: Article

References (85)

1. Differential effect of Clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in the raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn Schmiedberg
2. Authoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims
3. Changes in rat dopamine and serotonin function in vivo after prolonged administration of the specific 5HT inhibitor cytalopram
4. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
5. Pindolol induces a rapid improvement of depressed patients treated with serotonin re-uptake inhibitors
6. 18F ]-setoperone during depressive illness and antidepressant treatment with clomopramine
7. A review of central 5-HT receptors and their function
8. 18F]fluoroethyl)spiperone: In vivo biochemical and kinetic characterization in rodents, non human primates and human
9. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialisis study
10. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex
11. Current advances and trends in the treatment of depression
12. Current understanding of the mechanism of action of classical and newer antidepressant drugs
13. Repeated ECS differentially affects rat brain 5-HT1A and 5-HT2A receptor expression
14. 2 receptors in normal human brain with [3H]-n-propylnorapomorphine
15. Serotonin function and mechanism of action of antidepressant treatment: Effect of amitriptyline and desimipramine
16. In vivo [3H]spiperone binding: Evidence of accumulation in corpus striatum by agonist mediated receptor internalization
17. 2 receptor binding of 3-n-(2-fluoroethyl)spiperone in baboon brain
18. Postmortem neurochemical findings in suicide and depression: A study of the serotonergic system and imipramine binding in suicide victims
19. Platelet 5HT receptor binding during depressive illness and antidepressant treatment
20. Neurochemical alterations of serotonergic neuronal systems in depression
21. Serotoninergic modulation of striatal dopamine measured with positron emission tomography (PET) and and in vivo microdialysis
22. SPECT imaging of serotonin2 receptors in depression. Psychiatry research
23. A molecular and cellular theory of depression
24. Manipulations of synaptic serotonin: Discrepancy of effects on serotonin S1 and S2 sites
25. Dopaminergic and serotoninergic activity in drug-naive depressed patients assessed with PET and [F18]FESP
26. Estrogen control of central neurotransmission: Effect on mood mental state and memory
27. Regulation of mRNA encoding 5HT2 receptors in P!! cells through a post-transcriptional mechanism requiring activation of protein kinase C
28. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers
29. In vitro pharmacological profile of 3-N-(2-fluoroethyl)spiperone
30. 2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine-mediated behaviour following repeated electroconvulsive shock administration to rats
31. Some anticonvulsant drugs alter monoamine mediated behavior in mice in way similar to electroconvulsive shock: Implications for antidepressant therapy
32. Paroxetine, sertraline and fluvoxamine: New selective serotonin reuptake inhibitors
33. Autoradiographic analysis of [3H]ketanserin binding in the human brain post-mortem: Effect of suicide
34. 125I]epidepride
35. A rating scale for depression
36. Chronic fluoxetine treatment upregualates 5-HT uptake sites and 5HT2 receptors in rat brain: An autoradiographic study
37. Biochemical effect and drug levels in rats after long term treatment with the specific 5HT uptake inhibitor citalopram
38. 18F]-setoperone PET imaging
39. Electroconvulsive shock: Effects on biochemical correlates of neurotransmitter receptors in rat brain
40. Dimensions of delusional experience
41. Effects of repeated treatment with fluoxetine and citalopram, 5HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain
42. [11C]tropanyl benzilate-binding to muscarinic cholinergic receptors: Methodology and kinetic modeling alternatives
43. Pharmacokinetics of haloperidol, an update
44. Citalopram's ability to inverse the extracellular concentration of serotonin in the dorsal raphe prevents the drug effect in the frontal cortex
45. The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals
46. Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-2'-F18)fluoroethylspeperone and positron emission tomography
47. In vivo evidencies for the involvment of dopamine D2 receptors in striatum and anterior cyngulate gyrus in major depression
48. SSRIs differentiation: Pharmacology and pharmacokinetics
49. Brain 5-HT2 receptors in suicide victims: Violence of death, depression and effect of antidepressant medication
50. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor
51. Increased serotonin 2 and badrenergic receptor binding in the frontal corteces of suicide victims
52. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective seroptonin reuptake inhibitors
53. 5HT-receptor binding in post-mortem brain from patients with affective disorders
54. Fluoxetine but not triciclic antidepressants, potenziates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactine secretion in subjects with major depression or with obssessive compulsive disorder
55. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders
56. Serotonin in aging, late-life depression, and Alzheimer disease: The emerging role of functional imaging
57. 18F]setoperone PET imaging study
58. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography
59. Immunocytochemical localization and description of neurons expressing serotonin(2) receptors in the rat brain
60. Dosage records and treatment emergent symtoms (DOTES)
61. Fluvoxamine-clozapapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism
62. Serotonin receptors in the human brain IV autoradiographic mapping of serotonin-2 receptors
63. Chronic antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding
64. No carrier added 3-(2'-F-18)fluoroethylspiperone, a new dopamine receptor binding tracer for positron emission tomography
65. Effect of various antidepressant drugs on spontaneous firing rate of locus coeruleus and dorsal raphe neurones of the rat
66. Quantitative criteria for selection and use of labeled tracers for in vivo measurement of blood flow, metabolism and receptor-binding imaging techniques
67. 18F]altanserin in the human brain
68. Increased serotonin 2 bidning sites in frontal cortex of suicide victims
69. Current concepts on the mechanisms of action of antidepressant drugs
70. An evaluation of post-injection transmission measurement of PET
71. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: A critical review
72. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging
73. Receptor alteration associated with with serotoninergic agents: An autoradiographyc analysis
74. 18F]fluoroethylspiperone: Findings in disorders related to the dopaminergic system
75. Modelization: Application to the D2 receptors
76. Fluvoxamine: An updated review of its pharmacology, and therapeutic use in depressive illness
77. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex
78. Effect of age on dopamine and receptors measured by positron emission tomography in the living human brain
79. Rapid authomated algorithm for aligning and reslicing PET images
80. Decrease in brain serotonin 2 receptor binding in patients with major depression following desimipramine treatment: A positron emission tomography study with fluorine 18-labeled setoperone
81. 5-HT2 receptor changes in major depression
82. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression. A controlled stdy